Reported Sunday, HUTCHMED Highlights SACHI Phase III Data At ASCO 2025: Savolitinib Plus Osimertinib Shows Significant PFS Benefit In EGFR+ NSCLC With MET Amplification
Benzinga Newsdesk 1 year ago
Small Business
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —
— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —